LEXICON PHARMACEUTICALS, INC.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Business sectors
- pharmaceutical industry [1]
- Company / filing name
- LEXICON PHARMACEUTICALS, INC. [2]
- Headquarters location
- The Woodlands [1]
- Founded
- 1995 [1]
- Official website
- www.lexpharma.com ↗ [1]
- ISIN (reported securities)
- US5288723027 [1]
- CIK
- 1062822 [2]
- Country in background record
- United States [1]
- Symbols / exchanges
- LXRX (Nasdaq) [2]
Company positioning and business
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. [3]
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. [3]
Background text: Wikipedia contributors, Lexicon Pharmaceuticals. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Financial year, securities and disclosures
Listed securities: LXRX (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [2]
History and key events
Founding / inception date recorded in Wikidata. [1]
Financial results and regulatory disclosures
No individual financial documents have been indexed yet. Open the source to consult company disclosures. [2]
Related entities and concepts
Frequently asked questions
When was LEXICON PHARMACEUTICALS, INC. founded?
Founded: 1995. The linked source provides the background record. [1]
Where is the headquarters of LEXICON PHARMACEUTICALS, INC.?
Headquarters location: The Woodlands. The linked source provides the background record. [1]
Which business sectors are recorded for LEXICON PHARMACEUTICALS, INC.?
Business sectors: pharmaceutical industry. The linked source provides the background record. [1]
Sources and review dates
- Wikidata — company background record (CC0) ↗
- Company identity and profile data ↗
- Wikipedia contributors — Lexicon Pharmaceuticals (CC BY-SA 4.0) ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.